Anti-PD1 antibodies and their use as therapeutics and diagnostics
US9217034B2 · kind B2 · utility
36Cited by
0References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2014 |
| Grant date | Dec 22, 2015 |
| Priority date | — |
| Expiry date | Jun 17, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.